Janus Henderson Group PLC Purchases 31,871 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Janus Henderson Group PLC grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 545,173 shares of the biopharmaceutical company's stock after buying an additional 31,871 shares during the period. Janus Henderson Group PLC owned 0.43% of Halozyme Therapeutics worth $31,204,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Congress Asset Management Co. grew its holdings in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock worth $139,298,000 after acquiring an additional 1,988,238 shares during the period. Handelsbanken Fonder AB grew its stake in Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock worth $112,715,000 after purchasing an additional 856,200 shares during the period. Boston Trust Walden Corp bought a new stake in Halozyme Therapeutics in the second quarter worth approximately $23,211,000. Dimensional Fund Advisors LP lifted its stake in Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after buying an additional 209,530 shares during the period. Finally, Federated Hermes Inc. grew its position in shares of Halozyme Therapeutics by 37.8% during the 2nd quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company's stock worth $36,449,000 after buying an additional 191,030 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 60,000 shares of company stock valued at $3,425,000. Corporate insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HALO shares. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and boosted their target price for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Piper Sandler boosted their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a research report on Monday, November 4th. JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. Finally, HC Wainwright reissued a "buy" rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.11.

Halozyme Therapeutics Stock Up 0.7 %

NASDAQ HALO traded up $0.34 on Friday, reaching $48.40. The company had a trading volume of 905,788 shares, compared to its average volume of 2,149,973. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The stock has a market capitalization of $6.16 billion, a P/E ratio of 16.03, a P/E/G ratio of 0.44 and a beta of 1.23. The company's fifty day moving average is $52.43 and its 200 day moving average is $53.79.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.